AU2011313667B2 - Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction - Google Patents

Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction Download PDF

Info

Publication number
AU2011313667B2
AU2011313667B2 AU2011313667A AU2011313667A AU2011313667B2 AU 2011313667 B2 AU2011313667 B2 AU 2011313667B2 AU 2011313667 A AU2011313667 A AU 2011313667A AU 2011313667 A AU2011313667 A AU 2011313667A AU 2011313667 B2 AU2011313667 B2 AU 2011313667B2
Authority
AU
Australia
Prior art keywords
arctigenin
bone marrow
blood cell
group
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011313667A
Other languages
English (en)
Other versions
AU2011313667A1 (en
Inventor
Zhiquan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunan Pharmaceutical Group Corp
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Publication of AU2011313667A1 publication Critical patent/AU2011313667A1/en
Application granted granted Critical
Publication of AU2011313667B2 publication Critical patent/AU2011313667B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011313667A 2010-10-08 2011-10-08 Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction Active AU2011313667B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010299279.X 2010-10-08
CN201010299279.XA CN102440986B (zh) 2010-10-08 2010-10-08 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
PCT/CN2011/080543 WO2012045282A1 (zh) 2010-10-08 2011-10-08 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途

Publications (2)

Publication Number Publication Date
AU2011313667A1 AU2011313667A1 (en) 2013-05-02
AU2011313667B2 true AU2011313667B2 (en) 2015-08-27

Family

ID=45927226

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011313667A Active AU2011313667B2 (en) 2010-10-08 2011-10-08 Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction

Country Status (7)

Country Link
US (1) US20130190394A1 (enExample)
EP (1) EP2626071B1 (enExample)
JP (1) JP5744213B2 (enExample)
KR (1) KR101512495B1 (enExample)
CN (2) CN102440986B (enExample)
AU (1) AU2011313667B2 (enExample)
WO (1) WO2012045282A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397547B (zh) * 2010-09-19 2013-06-12 山东新时代药业有限公司 一种抗癌药物组合物
CN102440986B (zh) * 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
CN103027906B (zh) * 2011-10-08 2015-11-11 鲁南制药集团股份有限公司 牛蒡子苷元在治疗贫血疾病中的应用
EP2832355A4 (en) * 2012-03-26 2015-12-23 Kracie Pharma Ltd CANCER AGENT
CN103446100A (zh) * 2012-05-29 2013-12-18 鲁南制药集团股份有限公司 牛蒡子苷元的舌下含服制剂
JP5696191B2 (ja) * 2013-04-27 2015-04-08 クラシエ製薬株式会社 抗癌幹細胞剤
WO2015058664A1 (zh) * 2013-10-21 2015-04-30 鲁南制药集团股份有限公司 淫羊藿苷元在制备预防或治疗血细胞减少药物中的用途
CN104546823B (zh) * 2013-10-21 2019-08-30 鲁南制药集团股份有限公司 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途
WO2015156409A1 (ja) * 2014-04-10 2015-10-15 クラシエ製薬株式会社 抗癌剤および副作用軽減剤
JP6197077B1 (ja) * 2016-07-14 2017-09-13 クラシエ製薬株式会社 抗癌剤、放射線増感剤および食品組成物
CN110623960B (zh) * 2018-06-22 2022-08-19 成都山权江生物科技有限公司 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用
JP7675547B2 (ja) * 2021-04-01 2025-05-13 クラシエ株式会社 酸化ｌｄｌ増加抑制剤および酸化ｌｄｌ増加抑制用食品組成物
CN119462619B (zh) * 2024-11-06 2025-10-24 浙江大学 一种橙酮类化合物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101036643A (zh) * 2006-03-13 2007-09-19 海南盛科天然药物研究院有限公司 含牛蒡子苷元的药物组合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
CN1243103C (zh) * 2004-02-26 2006-02-22 广州中医药大学 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法
CA2637245A1 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc Inhibitors of tnf.alpha., pde4 and b-raf, compositions thereof and methods of use therewith
CN101134031B (zh) 2006-08-30 2012-05-09 山东绿叶天然药物研究开发有限公司 牛蒡子苷元在制备治疗或预防慢性肾功能衰竭及肾纤维化的药物中的用途
WO2011120339A1 (zh) * 2010-04-03 2011-10-06 鲁南制药集团股份有限公司 牛蒡苷元的微乳制剂
CN102440986B (zh) * 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101036643A (zh) * 2006-03-13 2007-09-19 海南盛科天然药物研究院有限公司 含牛蒡子苷元的药物组合物及其制备方法

Also Published As

Publication number Publication date
EP2626071A4 (en) 2014-04-02
HK1188122A1 (en) 2014-04-25
EP2626071B1 (en) 2016-01-13
CN103209693B (zh) 2015-10-07
EP2626071A1 (en) 2013-08-14
JP2013542205A (ja) 2013-11-21
CN102440986A (zh) 2012-05-09
WO2012045282A1 (zh) 2012-04-12
AU2011313667A1 (en) 2013-05-02
CN103209693A (zh) 2013-07-17
JP5744213B2 (ja) 2015-07-08
KR20130093125A (ko) 2013-08-21
US20130190394A1 (en) 2013-07-25
KR101512495B1 (ko) 2015-04-15
CN102440986B (zh) 2014-12-03

Similar Documents

Publication Publication Date Title
AU2011313667B2 (en) Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction
US10799521B2 (en) Use of icaritin in preparing medicament for preventing or treating hematocytopenia
JP2016534074A5 (enExample)
CN105566271B (zh) 双黄酮化合物及其制备治疗癌症的药物的用途
WO2012034519A1 (zh) 一种地榆鞣质提取物及其制备方法和用途
US20210030678A1 (en) Cannabinoid and cbd liposome formulations and uses thereof
CN104688722B (zh) 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途
RU2679903C1 (ru) Применение экстрактов женьшеня, гинзенозидов и производных гинзенозида для получения лекарственных препаратов или лечебных продуктов для лечения нарушений, вызванных цитомегаловирусной инфекцией
CN103179967A (zh) 抗肿瘤药物组合物
CN104688723B (zh) 淫羊藿苷元在制备治疗贫血药物中的应用
HK1188122B (en) Arctigenin for use in preventing or treating bone marrow suppression
CN107982240B (zh) 一种可精准溶出的炎琥宁肠溶颗粒及制备方法
CN109662968A (zh) 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
CN105535045A (zh) 常山碱盐酸盐及其制备方法和医药应用
CN108096239B (zh) 一种治疗脑胶质瘤和肝癌的药物组合物
CN100340232C (zh) 金薯叶止血合剂及其制备方法
CN110063988A (zh) 一种治疗神经母细胞瘤的药物组合物及其制备方法
WO2018133112A1 (zh) 一种地榆苷元注射剂及其制备方法和用途
CN120019814A (zh) 一种当归药物组合物纳米混悬剂的制备方法及其抗心肌缺血补血作用
CN114010657A (zh) 卵巢癌细胞在制备治疗胰腺癌药物中的应用
CN115590963A (zh) 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
CN110354168A (zh) 一种治疗肾透明细胞癌的药物组合物及其制备方法
CA2297933A1 (en) A method to improve immune function
CN103432134A (zh) 升高白细胞及治疗再生障碍性贫血的异粉防己碱药物及其制剂
CN103405436A (zh) 治疗白细胞减少症、再生障碍性贫血的轮环藤宁碱药物及其制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)